AVROBIO, Inc. (NASDAQ:AVRO) Short Interest Update

AVROBIO, Inc. (NASDAQ:AVROGet Free Report) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 181,600 shares, a growth of 11.3% from the April 30th total of 163,200 shares. Based on an average daily trading volume, of 219,000 shares, the short-interest ratio is presently 0.8 days. Currently, 0.5% of the company’s shares are short sold.

Insiders Place Their Bets

In other news, major shareholder Braden Michael Leonard purchased 469,753 shares of the stock in a transaction dated Monday, May 13th. The shares were purchased at an average price of $1.25 per share, with a total value of $587,191.25. Following the transaction, the insider now owns 4,471,380 shares in the company, valued at approximately $5,589,225. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new stake in shares of AVROBIO in the 3rd quarter valued at $33,000. Ikarian Capital LLC increased its stake in AVROBIO by 5.0% during the first quarter. Ikarian Capital LLC now owns 754,061 shares of the company’s stock worth $965,000 after purchasing an additional 35,802 shares during the period. FNY Investment Advisers LLC lifted its position in shares of AVROBIO by 77.8% during the fourth quarter. FNY Investment Advisers LLC now owns 400,000 shares of the company’s stock worth $544,000 after purchasing an additional 175,000 shares in the last quarter. Vazirani Asset Management LLC boosted its stake in shares of AVROBIO by 38.8% in the fourth quarter. Vazirani Asset Management LLC now owns 650,000 shares of the company’s stock valued at $884,000 after purchasing an additional 181,727 shares during the period. Finally, Affinity Asset Advisors LLC grew its holdings in shares of AVROBIO by 40.0% in the first quarter. Affinity Asset Advisors LLC now owns 700,000 shares of the company’s stock valued at $896,000 after purchasing an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 62.63% of the company’s stock.

AVROBIO Trading Up 2.8 %

AVRO opened at $1.48 on Monday. AVROBIO has a one year low of $0.88 and a one year high of $1.65. The business’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.31.

AVROBIO (NASDAQ:AVROGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. As a group, analysts predict that AVROBIO will post -0.48 earnings per share for the current year.

About AVROBIO

(Get Free Report)

AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.

Featured Articles

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.